Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that late-breaking data from the PHYOX Phase 1 trial of DCR-PHXC for the treatment of primary hyperoxaluria (PH) will be presented at the American Society of Nephrology (ASN) Annual Kidney Week 2018, being held October 23-28 in San Diego.
October 5, 2018
· 7 min read